This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-24 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Preparation and size === Particularly for older samples, it may be useful to enrich the amount of 14C in the sample before testing. This can be done with a thermal diffusion column. The process takes about a month and requires a sample about ten times as large as would be needed otherwise, but it allows more precise measurement of the 14C/12C ratio in old material and extends the maximum age that can be reliably reported. Once contamination has been removed, samples must be converted to a form suitable for the measuring technology to be used. Where gas is required, CO2 is widely used. For samples to be used in liquid scintillation counters, the carbon must be in liquid form; the sample is typically converted to benzene. For accelerator mass spectrometry, solid graphite targets are the most common, although gaseous CO2 can also be used. The quantity of material needed for testing depends on the sample type and the technology being used. There are two types of testing technology: detectors that record radioactivity, known as beta counters, and accelerator mass spectrometers. For beta counters, a sample weighing at least 10 grams (0.35 ounces) is typically required. Accelerator mass spectrometry is much more sensitive, and samples containing as little as 0.5 milligrams of carbon can be used.
== Battery designs and formats == Lithium-ion batteries may have multiple levels of structure. Small batteries consist of a single battery cell. Larger batteries connect cells in parallel into a module and connect modules in series and parallel into a pack. Multiple packs may be connected in series to increase the voltage. Batteries may be equipped with temperature sensors, heating/cooling systems, voltage regulator circuits, voltage taps, and charge-state monitors. These components address safety risks like overheating and short circuiting.
Unione Sportiva Milanese was founded on 16 January 1902 as a multi-sports club, for compete in different disciplines, by Ambrogio Ferrario, Romolo Buni and Gilbert Marley at the Caffè Verdi in Porta Nuova in Milan. In the spring of 1904 the football section was established on the initiative of some footballers and gymnasts who left first A.C. Milan and then Mediolanum (among of which Umberto Meazza), while the affiliation to the Italian Football Federation (FIF), the current FIGC, took place in 1905. The shirt was black and white checked, with white shorts and black socks. Red and white were the colors of the second jersey. By virtue of this choice, against the current compared to the norm of the others teams, were nicknamed "Gli Scacchi" (the chessmen). At the end of the 1927-1928 championship, U.S. Milanese was automatically promoted to the National Division but was also forced by the fascist regime to merge with the Internazionale in the new Società Sportiva Ambrosiana, whose management was appointed Ernesto Torrusio, president of U.S. Milanese at the time, in favor of the fact that the registration number used to register for the championship was precisely that of U.S. Milanese. For two years the S.S. Ambrosiana celebrated the U.S. Milanese using its historic logo and the black and white checkered collar: S.S. Ambrosiana won the Italian football championship in 1929/30 season. 1932 saw the end of the merger with Internazionale and the reconstitution of U.S. Milanese, which was reborn only as a sports club without the football section. In 1945 U.S.
Sources: en.wikipedia.org
The Bergmann degradation makes use of the azide degradation described by the Curtius rearrangement. Curtius also attempted to degrade benzoylated amino acids; however, his method involved splitting the carbamate with strongly energetic treatment with acids, which lead to decomposition of the resultant aldehyde and acid amides. This convinced Bergmann that Curtius' azide degradation could be followed by treatment with benzyl alcohol (his carbobenzoxy method) to isolate the resultant amino acid aldehyde and residual peptide amide for sequencing purposes.
== Cited sources == Charatan, Fred (2006). "Gulf war symptoms do not constitute a syndrome". BMJ. 333 (7569): 618. doi:10.1136/bmj.333.7569.618-b. JSTOR 40700302. PMC 1570822. PMID 16990302. Greenberg, Neil; Iversen, Amy C.; Unwin, Catherin; Hull, L.; Wessely, S. (2004). "Screening for depleted uranium in the United Kingdom armed forces: who wants it and why?". Journal of Epidemiology and Community Health. 58 (7): 558–561. doi:10.1136/jech.2003.014142. PMC 1732813. PMID 15194715. Moszynski, Peter (2003). "Royal Society warns of risks from depleted uranium". BMJ. 326 (7396): 952. doi:10.1136/bmj.326.7396.952. JSTOR 25454350. PMC 1125878. PMID 12727744. Mould, Richard F. (2001). "Radiation dose from depleted uranium can now be measured". BMJ. 322 (7290): 865–866. doi:10.1136/bmj.322.7290.865/a. JSTOR 25466697. PMC 1120031. PMID 11321019. S2CID 683662. Royal Society working group on the health hazards of depleted uranium munitions (2002). The health hazards of depleted uranium munitions: Part II (Report). London, England: The Royal Society.
== Genomics == The gene is located on long arm of chromosome 11 (11q13) between base pairs 64,570,985 and 64,578,765. It has 10 exons and encodes a 610-amino acid protein. Over 1300 mutations have been reported to date (2010). The majority (>70%) of these are predicted to lead to truncated forms are scattered throughout the gene. Four - c.249_252delGTCT (deletion at codons 83-84), c.1546_1547insC (insertion at codon 516), c.1378C>T (Arg460Ter) and c.628_631delACAG (deletion at codons 210-211) have been reported to occur in 4.5%, 2.7%, 2.6% and 2.5% of families.
Sources: en.wikipedia.org
== Further reading == Carbone, Christine E.; Loveland, Anna B.; Gamper, Howard B.; Hou, Ya-Ming; Demo, Gabriel; Korostelev, Andrei A. (December 2021). "Time-resolved cryo-EM visualizes ribosomal translocation with EF-G and GTP". Nature Communications. 12 (1): 7236. doi:10.1038/s41467-021-27415-0. PMC 8668904.
The carbon dioxide produced by this reaction is nonpolar and small, and can diffuse out of the mitochondria and out of the cell. In prokaryotes, which have no mitochondria, this reaction is either carried out in the cytosol, or not at all.
and associated with familial thrombophilia. In 1994, the relatively common genetic mutation that produces Factor VLeiden was noted (Bertina et al.). Two years later, Gla-domainless APC was imaged at a resolution of 2.8 Ångströms. Beginning with the PROWESS clinical trial of 2001, it was recognised that many of the symptoms of sepsis may be ameliorated by infusion of APC, and mortality rates of septic patients may be significantly decreased. Near the end of that year, Drotrecogin alfa (activated), a recombinant human activated protein C, became the first drug approved by the U.S. FDA for treating severe sepsis. In 2002, Science published an article that first showed protein C activates protease-activated receptor-1 (PAR-1) and this process accounts for the protein's modulation of the immune system.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.